يعرض 18,461 - 18,480 نتائج من 21,342 نتيجة بحث عن '(( significant decrease decrease ) OR ( significantly reduced decrease ))', وقت الاستعلام: 0.60s تنقيح النتائج
  1. 18461
  2. 18462

    Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

    منشور في 2025
    "…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
  3. 18463

    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

    منشور في 2025
    "…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
  4. 18464

    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

    منشور في 2025
    "…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
  5. 18465
  6. 18466

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

    منشور في 2025
    "…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
  7. 18467
  8. 18468
  9. 18469

    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

    منشور في 2025
    "…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
  10. 18470

    Rht1 functions in cell cycle progression and modulates fluconazole susceptibility. حسب Ci Fu (148006)

    منشور في 2025
    "…Log rank (Mantel-Cox) test assessed significant difference between wild type and <i><i>rht1</i></i>Δ/Δ. …"
  11. 18471

    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

    منشور في 2025
    "…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
  12. 18472
  13. 18473

    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... حسب Alessandro Colletta (1509928)

    منشور في 2025
    "…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
  14. 18474

    Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

    منشور في 2025
    "…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
  15. 18475

    Genetic interaction between <i>Zrf1</i> and RISC components regulates ISC proliferation during midgut damage. حسب Joshua Shing Shun Li (22505522)

    منشور في 2025
    "…</b> Box plots show median, quartiles, and range. Statistical significance determined by Student’s t-test; ns = not significant, **p < 0.01, ****p < 0.0001.…"
  16. 18476

    Figure 5 from Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma حسب Marianna Carrabotta (8193039)

    منشور في 2025
    "…<b>A,</b> Inhibition of PDX-CDS #4-C tumor growth after treatments with trabectedin and/or NVP-BEZ235. Significant reduction in tumor growth was observed after single treatments (*, <i>P</i> < 0.05, Student <i>t</i> test) but the inhibition increased after combination of the two drugs (significance was at least ***, <i>P</i> < 0.001, Student <i>t</i> test starting from day 23) or to single treatments (*, <i>P</i> < 0.05). …"
  17. 18477

    Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

    منشور في 2025
    "…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
  18. 18478

    Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... حسب Alessandro Colletta (1509928)

    منشور في 2025
    "…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
  19. 18479

    Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... حسب Alessandro Colletta (1509928)

    منشور في 2025
    "…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …"
  20. 18480